首页> 美国卫生研究院文献>Antioxidants >Novel Phenothiazine/Donepezil-like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer’s Disease
【2h】

Novel Phenothiazine/Donepezil-like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer’s Disease

机译:具有抗氧化活性的新型吩噻嗪/多奈哌齐样杂交体用于治疗阿尔茨海默病的多靶点方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer’s disease (AD) is a complex multi-factorial neurodegenerative disorder for which only few drugs (including donepezil, DPZ) are available as symptomatic treatments; thus, researchers are focusing on the development of innovative multi-target directed ligands (MTDLs), which could also alter the course of the disease. Among other pathological factors, oxidative stress has emerged as an important factor in AD that could affect several pathways involved in the onset and progression of the pathology. Herein, we propose a new series of hybrid molecules obtained by linking a phenothiazine moiety, known for its antioxidant properties, with N-benzylpiperidine or N-benzylpiperazine fragments, mimicking the core substructure of DPZ. The investigation of the resulting hybrids showed, in addition to their antioxidant properties, their activity against some AD-related targets, such as the inhibition of cholinesterases (both AChE and BChE) and in vitro Aβ1-40 aggregation, as well as the inhibition of the innovative target fatty acid amide hydrolase (FAAH). Furthermore, the drug-likeness properties of these compounds were assessed using cheminformatic tools. Compounds 11d and 12d showed the most interesting multi-target profiles, with all the assayed activities in the low micromolar range. In silico docking calculations supported the obtained results. Compound 13, on the other hand, while inactive in the DPPH assay, showed the best results in the in vitro antioxidant cell assays conducted on both HepG2 and SHSY-5Y cell lines. These results, paired with the low or absent cytotoxicity of these compounds at tested concentrations, allow us to aim our future research at the study of novel and effective drugs and pro-drugs with similar structural characteristics.
机译:阿尔茨海默病 (AD) 是一种复杂的多因素神经退行性疾病,只有少数药物(包括多奈哌齐、DPZ)可用于对症治疗;因此,研究人员正专注于开发创新的多靶点定向配体 (MTDL),这也可能改变疾病的进程。在其他病理因素中,氧化应激已成为 AD 的一个重要因素,它可能影响参与病理发生和进展的几个途径。在此,我们提出了一系列新的杂化分子,通过将以其抗氧化特性而闻名的吩噻嗪部分与 N-苄基哌啶或 N-苄基哌嗪片段连接起来,模拟 DPZ 的核心亚结构。对所得杂交体的研究表明,除了它们的抗氧化特性外,它们还对一些 AD 相关靶标具有活性,例如抑制胆碱酯酶(AChE 和 BChE)和体外 Aβ1-40 聚集,以及抑制创新靶标脂肪酸酰胺水解酶 (FAAH)。此外,使用化学信息学工具评估了这些化合物的药物相似性。化合物 11d 和 12d 显示出最有趣的多靶标谱,所有测定的活性都在低微摩尔范围内。计算机对接计算支持获得的结果。另一方面,化合物 13 虽然在 DPPH 测定中无活性,但在对 HepG2 和 SHSY-5Y 细胞系进行的体外抗氧化细胞测定中显示出最佳结果。这些结果,再加上这些化合物在测试浓度下的低细胞毒性或不存在细胞毒性,使我们能够将未来的研究目标放在研究具有相似结构特征的新型有效药物和前体药物上。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号